Anupam Rasayan India Gets CRISIL A+/Stable Rating Reaffirmation After Successful Acquisition Funding
CRISIL Ratings removed Anupam Rasayan India from 'Rating Watch Negative' and reaffirmed A+/Stable ratings on Rs 1369.82 crore facilities. The positive action follows successful $150 million acquisition funding through $41 million debt and $109 million equity from Oaktree Capital. The company showed strong operational improvement with revenue rising to Rs 1,729 crore in 9M FY26 from Rs 938 crore previously, reducing inventory days from 500 to 310 days.

*this image is generated using AI for illustrative purposes only.
Anupam Rasayan India Limited has received positive news from CRISIL Ratings, which has removed the company from 'Rating Watch with Negative Implications' and reaffirmed its credit ratings following successful acquisition funding and improved operational performance.
Rating Action Details
CRISIL Ratings has reaffirmed the company's credit ratings across its bank loan facilities worth Rs 1369.82 crore. The rating action reflects the completion of funding arrangements for the company's strategic acquisition and demonstrated improvements in working capital management.
| Rating Category: | Rating Details |
|---|---|
| Total Bank Loan Facilities: | Rs 1369.82 crore |
| Long Term Rating: | CRISIL A+/Stable (Removed from Rating Watch Negative) |
| Short Term Rating: | CRISIL A1 (Removed from Rating Watch Negative) |
Acquisition Funding Success
The ratings were initially placed on 'Watch Negative' following the company's announcement to acquire 100% equity in Jayhawk Fine Chemicals LLC, a US-based specialty chemicals company, for $150 million. The resolution of the watch status was driven by the successful completion of funding arrangements.
The company structured the acquisition funding through a balanced approach:
- Debt component: $41 million raised through debt financing
- Equity component: $109 million of Class B non-voting equity infused by Altix XII Pte Ltd, a fund managed by Oaktree Capital Management LLP
Operational Performance Improvements
The company demonstrated significant operational improvements during the first nine months of fiscal 2026. Revenue performance showed substantial growth, reaching Rs 1,729 crore compared to Rs 938 crore in the corresponding period of the previous fiscal year.
This revenue improvement contributed to better working capital management:
| Working Capital Metric: | Previous Period | Current Period |
|---|---|---|
| Inventory Days: | 500 days | 310 days |
| Revenue (9M FY26): | Rs 938 crore | Rs 1,729 crore |
Business Strengths and Market Position
CRISIL highlighted the company's strong business risk profile, backed by its established market position in custom synthesis and manufacturing of specialty chemicals. With nearly four decades of experience, the group serves 75 clients globally, including 31 multinational companies across agrochemicals, personal care, pharmaceuticals, and specialty segments.
The rating agency noted the company's diversified revenue streams, with pharmaceutical and polymer segments expected to contribute more than 30% of total revenue in fiscal 2026. The acquisition of Tanfac Industries provides backward integration benefits, securing supply of critical raw materials like hydrogen fluoride and potassium fluoride.
Financial Risk Profile
The company maintains a strong financial risk profile with healthy capital structure metrics. As of September 30, 2025, the networth stood at Rs 3,197.3 crore with a total outside liabilities to adjusted networth ratio of 0.6 times, compared to Rs 2,935.6 crore and 0.74 times as of March 31, 2025.
| Financial Metric: | March 31, 2025 | March 31, 2024 |
|---|---|---|
| Operating Income: | Rs 1,438.72 crore | Rs 1,476.29 crore |
| Reported PAT: | Rs 159.85 crore | Rs 167.42 crore |
| PAT Margin: | 11.11% | 11.34% |
| Debt/Networth: | 0.45 times | 0.37 times |
| Interest Coverage: | 3.55 times | 4.34 times |
Outlook and Future Prospects
CRISIL assigned a 'Stable' outlook to the long-term rating, expecting the group's operating performance to continue benefiting from its established brand and comfortable financial risk profile. The rating agency anticipates further improvement in the working capital cycle with the commercialization of new products and expects the company to maintain its market position through expansion into high-value fluorination chemistry products and polymer applications.
Historical Stock Returns for Anupam Rasayan
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.25% | -4.27% | -3.62% | +14.42% | +57.52% | +136.05% |






























